XJ-4-85 Shrinks Mouse Melanoma Tumors in 2 Weeks by Overdriving Sugar Use
Updated
Updated · gadgetreview.com · Aug 6
XJ-4-85 Shrinks Mouse Melanoma Tumors in 2 Weeks by Overdriving Sugar Use
3 articles · Updated · gadgetreview.com · Aug 6
Summary
Daily XJ-4-85 injections over 2 weeks left mice with significantly smaller melanoma tumors than every comparison group, while the payload fragment XJ-4-119 alone worked less well.
The compound hits cancer metabolism in two steps: it drives PFKL into overactivity to flood cells with sugar intermediates, then releases XJ-4-119 to block CPT2 and shut off long-chain fat burning.
Selectivity screens found strong engagement at just 1 lysine site on PFKL across roughly 9,000 protein sites, with CPT2 standing out from more than 7,000 proteins in thermal-stability profiling.
Genetic knockout tests showed PFKL is the main driver—removing it made tumors about 5 times larger under treatment after 9 days, while deleting CPT2 reduced efficacy less sharply.
No human trials have started, and the 2-week mouse study leaves major safety and resistance questions because both targets also function in healthy heart, liver and skeletal muscle.